Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women
A Randomized Controlled Trial

Kerrie M. Sanders, PhD
Amanda L. Stuart, BAppSc
Elizabeth J. Williamson, MA, PhD
Julie A. Simpson, PhD
Mark A. Kotowicz, MBBS, FRACP
Doris Young, MD, MBBS, FRACGP
Geoffrey C. Nicholson, PhD, FRACP

The results of randomized controlled trials investigating the effects of cholecalciferol (vitamin D) supplementation on falls and fractures have been inconsistent.1-13 Some meta-analyses conclude that 700 to 800 IU of vitamin D daily reduces fracture risk by 13% to 26%,14-18 whereas others conclude that vitamin D is ineffective. A Cochrane analysis19 and the Vitamin D Individual Patient Analysis of Randomized Trials (DIPART) group,20 published after this study commenced, showed a nonstatistically significant increase in hip fracture risk associated with vitamin D supplementation.19-21 Studies have observed those living in long-term care facilities as having greater fracture risk reduction than community-dwelling elders. Similarly, fewer fractures were observed in participants whose study treatment was coadministered with calcium.4,5,16,22 Furthermore, many studies have found treatment adherence to be low1,2,6 and fracture risk reduction was greater among adherent than nonadherent participants.

For editorial comment see p 1861.
HIGH-DOSE VITAMIN D AND FALLS AND FRACTURES IN WOMEN

ciferol administered intramuscularly as a single annual dose. The study was designed so that the vitamin D treatment would prevent decreases in 25-hydroxycholecalciferol over winter,25 address low adherence, and be a practical intervention easily translated to clinical practice.

METHODS

Study Design

The Vital D study was a single-center, double-blind, randomized, placebo-controlled trial involving women 70 years or older residing in southern Victoria, Australia (latitude 38°S). The participants were recruited between 2003 and 2005 and were randomly assigned to receive either a single oral dose of cholecalciferol 500 000 IU or matched placebo each year for 3 to 5 years (in autumn or winter). Participants were followed up for 12 months after their last dose of study medication in 2007.

The study was approved by the institutional review boards of Barwon Health and the University of Melbourne and carried out in compliance with the Helsinki Declaration. All participants provided written informed consent.

The study recruited 2317 community-dwelling women as previously described.26 Invitation letters were sent to all age-eligible women listed on the electoral roll of the region surrounding the study center. Voting is compulsory in Victoria. Women were included in the study if they were at higher risk of hip fracture,27 defined by criteria such as maternal hip fracture, past fracture, or self-reported faller.28 Women were excluded if they could not provide informed consent or information about falls or fractures; permanently resided at a high-level care facility; had an albumin-corrected calcium level higher than 2.65 mmol/L; or had a creatinine level higher than 150 µmol/L, or currently took vitamin D doses of 400 IU or more, calcitriol, or antifracture therapy. (To convert calcium from mmol/L to mg/dL, divide by 0.25; creatinine from µmol/L to ng/mL, divide by 2.496.)

Eligible participants were randomized to receive either 500 000 IU of cholecalciferol or identical placebo. Allocation was performed by an independent statistician using computer-generated randomization of numbers performed in blocks of 500. Treatment allocation status was e-mailed directly to the hospital clinical trials pharmacist responsible for dispensing study medication. The participants and study staff were blinded to intervention group.

Study medication was supplied by PSM Healthcare, Auckland, New Zealand. Ten tablets were mailed to participants annually (March-August, determined by recruitment date) with instructions to take all tablets on a single day. Study staff confirmed by telephone the ingestion of study medication within 2 weeks. Subsequent dosing occurred within 2 weeks of the anniversary of the first dose.

Outcome Measures

Participants’ age, calcium intake, and fracture-risk profile were collected at baseline by questionnaire. Falls were defined as “an event reported either by the faller or a witness, resulting in a person inadvertently coming to rest on the ground or another lower level, with or without loss of consciousness or injury.”28 This definition was explained to participants and reinforced twice yearly via newsletter.

All contact with participants was by mail and telephone. Falls and fractures were recorded using postcard calendars completed daily by writing F if they had a fall, fracture, or both and N if they did not and were returned monthly by prepaid post.29 Participants unable to send postcards were telephoned monthly.

When a fall or fracture was indicated, a standardized questionnaire recording details was administered by telephone. Only fractures radiologically confirmed were included in the analyses. Seventy-three self-reports...
were unconfirmed because of 1 of the following reasons: (1) not x-rayed (eg, suspected rib fracture), 13 vitamin D vs 15 placebo; (2) radiologist’s report stated no fracture, 19 vitamin D vs 23 placebo; and (3) vertebral deformity with less than 20% height reduction, 2 vitamin D vs 1 placebo. Falls were classified as “resulting from active behavior” when the participant, at the time of the fall, was walking, gardening, shopping, doing housework, engaging in sports, rushing, or climbing a ladder or chair. Other circumstances surrounding falls were classified as nonactive behavior. Calcium intake was quantified annually by questionnaire.30

The 150 substudy participants were randomly selected and results were asayed in a manner blinded to treatment group. Serum 25-hydroxycholecalciferol (DiaSorin, Stillwater, Minnesota) and intact parathyroid hormone ([PTH]; Advia Centaur Siemens, Deerfield, Illinois) was measured at baseline and 12 months after dose. In 2006 and 2007, measurements were also performed 1 and 3 months after dose.

Sample Size

Based on 80% power and 5% level of significance, we calculated that 6855 person-years were needed to detect 22% relative difference in fracture rates.7 Our previous work demonstrates a 3.3% fracture rate among women older than 70 years31 and suggests that hip and forearm fractures could be reduced by 16% and 31%, respectively, if summer-fall forearm fractures could be reduced by dwelling women of the same age.

3-fold higher than community-fracture, we estimated that our study months after dose.

Statistical Methods

All analyses were intention-to-treat. Fall and fracture data were inclusive from date of first study medication to either completion or the last complete month of data (withdrawn or lost to follow-up). Initial comparisons of outcome measures between treatment groups were performed using χ² tests or Wilcoxon rank-sum tests, as appropriate. The primary outcome measures, numbers of falls and fractures, were analyzed using Poisson regression models with robust standard errors to allow for nonindependence of multiple events for the same participant. The models included only treatment group but were also fitted adjusting for baseline calcium intake (<800 mg, 800-1100 mg, 1100-1300 mg, or >1300 mg) and age. The data were also analyzed using negative binomial regression models that explicitly allow for overdispersion. For comparison with similar studies, time to first fracture and fall was analyzed using Cox proportional hazards models. Kaplan-Meier plots of cumulative incidence are presented.

Post hoc analyses were undertaken to investigate the relationship between the treatment effect and time since ingesting the annual dose. Each year of follow-up was split into 2 follow-up segments: at 3 months and 9 months after dosing. A generalized estimating equation approach was used to allow for correlation between a participant’s falls and fractures at the different time periods. Estimated incidence rate ratios (RRs) for 0 through 3 months and 4 through 12 months after dosing are presented with the P value testing for homogeneity of the 2 incidence RRs.

No adjustment was made for multiple testing. All P values are 2-sided to detect differences, P < .05. Analyses were performed in Stata 10.1 (StataCorp, College Station, Texas).

Although adverse events were monitored, there was not a data and safety monitoring board or stopping rules because at the time the study commenced, these were not usual practice for vitamin D randomized controlled trials. US Food and Drug Administration and European Medicines Agency guidelines did not indicate a need, and based on published data, we had no expectation of harm.

RESULTS

Enrollment and outcomes are shown in Figure 1. There was no difference between the treatment groups in the proportion who withdrew nor in the reasons for withdrawal. All other par-
ticipants were followed up until the predetermined study end in 2008. The proportion who commenced antifracture therapy during the intervention period did not differ (90 of 1131 in the vitamin D vs 87 of 1125 in the placebo group; \( P = .84 \)).

The groups did not differ significantly by age, risk profile, calcium intake, or biochemistry (Table 1). The proportion who received medication in each month (March-August) was evenly distributed between the groups (\( P = .66 \)).

On 163 occasions, participants did not receive a dose of study medication but continued to participate in the study and were included in the analysis. On 105 of these occasions, doses were held because 44 in the vitamin D and 61 in the placebo group reported taking more than 400 IU of vitamin D supplementation. On 58 occasions, 33 in the vitamin D and 25 in the placebo group declined a dose of study medication. Ingestion of study medication was confirmed annually for all other participants. At the end of the study, approximately 6% in the placebo group (as of 2008, 65 of 1125) and 3% (38 of 1131) in the vitamin D group were taking more than 400 IU/d of vitamin D supplements.

### Fall Outcomes

The 2256 participants had a total of 3404 falls over 6923 person-years. Seventy-four percent of 1131 women in the vitamin D group and 68% of 1125 women in the placebo group had at least 1 fall (Table 2). The vitamin D group had 2892 falls at a rate of 83.4 per 100 person-years vs 2512 in the placebo group at a rate of 72.7 per 100 person-years (incidence RR, 1.15; (95% CI, 1.02-1.30); \( P = .03 \); Table 3). The results did not change after adjusting for age nor when analyzed using negative binomial regression to allow for overdispersion. The cumulative incidence of first fall was increased in the vitamin D group (hazard ratio [HR], 1.16; 95% CI, 1.05-1.28; \( P = .003 \); Figure 2).

Increased falls in the vitamin D group were observed for each classification of falls: falls with fracture, falls without fracture, and falls with soft tissue injury (Table 2). The proportion of falls that resulted in a physician visit did not differ: 27.2% (778 of 2892) in the vitamin D group vs 26.1% (657 of 2512) in the placebo group.

### Fracture Outcomes

One hundred fifty-five women receiving vitamin D sustained 171 fractures and 125 receiving placebo sustained 135 fractures (Table 2). The fracture rate in the vitamin D group was 4.9 per 100 person-years vs 3.9 in the placebo group. The incidence RR for fracture was 1.26 (95% CI, 1.00-1.59; \( P = .047 \)) compared with the placebo group. Similarly, the nonvertebral fracture RR was 1.28 in the vitamin D group (incidence RR, 1.28; 95% CI, 1.00-1.65; \( P = .06 \)). The HR cumulative incidence of first fracture was 1.26 in the vitamin D group compared with the placebo group (95% CI, 0.99-1.59; \( P = .06 \); Figure 2).

### Table 2. Summary of Falls and Fractures

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Vitamin D (n = 1131)</th>
<th>Placebo (n = 1125)</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention, median (IQR), y</td>
<td>2.96 (2.92-3.00)</td>
<td>2.96 (2.92-3.00)</td>
<td>.60</td>
</tr>
<tr>
<td>Total intervention time, y</td>
<td>3467.8</td>
<td>3457.4</td>
<td></td>
</tr>
<tr>
<td>Total No. of falls and fractures</td>
<td>2026</td>
<td>2538</td>
<td>.01</td>
</tr>
<tr>
<td>Falls, No. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>294 (26.0)</td>
<td>356 (31.6)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>279 (24.7)</td>
<td>246 (21.9)</td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>558 (49.3)</td>
<td>523 (46.5)</td>
<td></td>
</tr>
<tr>
<td>≥4</td>
<td>258 (22.8)</td>
<td>235 (20.9)</td>
<td></td>
</tr>
<tr>
<td>≥8</td>
<td>72 (6.4)</td>
<td>55 (4.9)</td>
<td></td>
</tr>
<tr>
<td>≥1 fall</td>
<td>837 (74.0)</td>
<td>769 (68.4)</td>
<td>.003</td>
</tr>
<tr>
<td>Falls and outcomes, No.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total falls</td>
<td>2892</td>
<td>2512</td>
<td></td>
</tr>
<tr>
<td>With fracture</td>
<td>137</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>Without fracture</td>
<td>2755</td>
<td>2403</td>
<td></td>
</tr>
<tr>
<td>With soft tissue injury</td>
<td>1710</td>
<td>1488</td>
<td>.02</td>
</tr>
<tr>
<td>Fractures, No.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total fractures</td>
<td>171</td>
<td>135</td>
<td></td>
</tr>
<tr>
<td>Without fall</td>
<td>34</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>≥1 Nonvertebral fracture</td>
<td>124</td>
<td>101</td>
<td></td>
</tr>
</tbody>
</table>

\( ^a \)Results are expressed as number (%) of participants in the groups unless otherwise specified.

\( ^b \) \( ^c \) Tests for binary outcomes, Wilcoxon rank-sum tests for continuous outcomes.

\( ^d \) Falls resulting in a fracture are counted as one event.

\( ^e \) Counting each event; one person can contribute more than once.

\( ^f \) Refers to bruise, abrasion, or muscle injury without fracture; \( P \) value refers to incidence rate ratio (1.15, 95% confidence interval, 1.02-1.28).

\( ^g \) The number of participants with at least 1 nonvertebral fracture. The number of participants with at least 1 fracture at the following sites was (vitamin D, placebo groups, respectively) hip (19, 15), colles (26, 23), other forearm (14, 7), vertebral (35, 28), humerus (15, 14), ribs (6, 7), clavicle/scapula (4, 1), pelvis (8, 4), upper leg/patella (8, 6), lower leg (6, 5), ankle (8, 12), foot/toes (17, 12), hand/fingers (6, 3), and skull/facial bones (8, 4).
The frequency of falls among women who sustained a fracture did not differ between groups with a median of 2 falls (interquartile range [IQR], 1-4) throughout the study course.

Temporal Effect of Annual Dose
The incidence RR of falls in the vitamin D group was 1.31 in the first 3 months (95% CI, 1.12-1.54) following dosing, but only 1.13 (95% CI, 0.99-1.29) during the remaining 9 months of the year (P value for homogeneity=.02, TABLE 4). The temporal pattern of excess falls was observed each year except the first year.

Although not statistically significant, the temporal pattern observed in falls was also observed in fractures (Table 3). The vitamin D fracture incidence RR compared with the placebo group was 1.53 (95% CI, 0.95-2.46) in the first 3 months after dosing and 1.18 (95% CI, 0.91-1.54) during the following 9 months.

Calcium Intake and Questionnaire Data
The proportion of participants with calcium intake of less than 800 mg/d decreased from 33% at baseline to 27% over the subsequent annual assessments, whereas the proportion consuming 1100 mg or more increased from 40% to 46%. There was no difference between the groups in the categories of calcium intake (Table 1). The median daily calcium intake was 976 mg (IQR, 691-1311 mg).

The increased risk of both falls and fractures in the vitamin D group did not change after adjusting for baseline calcium intake. The overall calcium-adjusted incidence RR of falling was 1.16 (95% CI, 1.03-1.31); for fracture, 1.25 (95% CI, 0.99-1.58; Table 3) in the vitamin D group. The groups had a similar proportion of falls occurring during active behavior (79% vs 81%, respectively).

Biochemistry Substudy
Ninety-one percent (137 of 150) of those invited to participate in the biochemistry substudy consented. Baseline samples were collected from 133 participants, 75 from the vitamin D group and 58 from the placebo group. One sample from each group was excluded because 25-hydroxycholecalciferol levels of 123 nmol/L and 115 nmol/L suggested that the women were taking more than 400 IU vitamin D supplementation per day.

At baseline, the median 25-hydroxycholecalciferol level was 49 nmol/L (IQR, 40-63; normal lower limit, >50 nmol/L). Less than 3% of the substudy participants had 25-hydroxycholecalciferol levels lower than 25 nmol/L. The 25-hydroxycholecalciferol and PTH levels did not differ between the groups (Table 1). Approximately half of the substudy participants had 25-hydroxycholecalciferol levels of 50 nmol/L or lower (vitamin D, 45.9% vs 61.4%, placebo) but less than 5% had levels of 25 nmol/L or lower (vitamin D, 4.0% vs 3.5%, placebo).

In each year of the study, samples were obtained 12 months after dose (ie, just prior to the second through fifth annual dose administrations and at study completion). There was a marked increase in 25-hydroxycholecalciferol levels in the vitamin D group with some evidence of this increase trailing off toward the end of the trial. The median 25-hydroxycholecalciferol levels 12 months after dose in the vitamin D group ranged from 55 nmol/L to 74 nmol/L over the 5 intervals with individual values ranging from 25 nmol/L to 120 nmol/L (Figure 3). The medians and IQRs of the PTH levels remained stable 12 months after dosing.

In 2006 and 2007, samples were collected at 1 and 3 months after dose in 102 (74%) of the substudy participants. The median 25-hydroxycholecalciferol level in the vitamin D group 1 month after dose was slightly more than 120 nmol/L with 82% at 100 nmol/L or higher and 24% at

<table>
<thead>
<tr>
<th>Vitamin D</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>123 nmol/L</td>
<td>115 nmol/L</td>
</tr>
<tr>
<td>49 nmol/L</td>
<td>48 nmol/L</td>
</tr>
</tbody>
</table>

This analysis censors data after first fall or fracture. Time to first fracture and fall was analyzed using Cox proportional hazards models. CI indicates confidence intervals; HR, hazard ratio.

Table 4. Temporal Pattern of Risk in Falls and Fracture 0 to 3 Months and 4 to 12 Months After Treatment

<table>
<thead>
<tr>
<th>Incidence Rate Ratio for Vitamin D Group, Estimate (95% Confidence Interval)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Falls</td>
<td></td>
</tr>
<tr>
<td>Within 3</td>
<td>1.31 (1.12-1.54)</td>
</tr>
<tr>
<td>After 3</td>
<td>1.13 (0.99-1.29)</td>
</tr>
<tr>
<td>Fracture</td>
<td></td>
</tr>
<tr>
<td>Within 3</td>
<td>1.53 (0.95-2.46)</td>
</tr>
<tr>
<td>After 3</td>
<td>1.18 (0.91-1.54)</td>
</tr>
</tbody>
</table>

©2010 American Medical Association. All rights reserved.
Serum 25-hydroxycholecalciferol levels in the vitamin D group differ from those of the placebo group at all 12-month assessments after dose ($P<.05$). The medians are shown as the horizontal bar within the rectangle and the interquartile range as the ends of the rectangle. The 5th and 95th percentiles are shown as lines (whiskers), and the closed circles represent outliers. The proportion of biochemistry substudy participants categorized into 25-hydroxycholecalciferol status is (vitamin D group, $n=74$ vs placebo group, $n=57$, respectively) 25 nmol/L or less: 4% vs 3.5%; 26 to 50 nmol/L: 41.9% vs 57.9%; 51 to 75 nmol/L: 44.5% vs 33.3%; 75 nmol/L or higher: 9.5% vs 5.3%. To convert 25-hydroxycholecalciferol from nmol/L to ng/mL, divide by 2.496.

**Figure 3.** Serum 25-Hydroxycholecalciferol Levels at Baseline and 12 Months After Dose for Each Year of the Intervention

Serum 25-hydroxycholecalciferol levels increased substantially 1 month after dosing and thereafter declined toward baseline but remaining on average 41% higher than levels in the placebo group. The pattern is consistent with serial measurements done in older New Zealanders supplemented with 500 000 IU cholecalciferol.

Only 1 other study has reported an increase in fracture associated with vitamin D treatment. Participants (4354 men, 5086 women) 75 years or older received an annual injection of 300 000 IU vitamin D$_2$ as ergocalciferol or placebo. In men, treatment had no effect on fractures. However women treated with vitamin D had increased risk of nonvertebral (HR, 1.21), hip/femur (HR, 1.80), and hip/femur/wrist/forearm fractures were considered related to study medication.

**COMMENT**

Contrary to our hypothesis, participants receiving annual high-dose oral cholecalciferol experienced 15% more falls and 26% more fractures than the placebo group. Women not only experienced excess fractures after more frequent falls but also experienced more fractures that were not associated with a fall. A post hoc analysis found that the increased likelihood of falls in the vitamin D group was exacerbated in the 3-month period immediately following the annual dose and a similar temporal trend was observed for fractures. An increased risk (albeit, not significant because of smaller numbers) of falls and fracture in the vitamin D group was apparent for each year of the intervention. The results were similar after adjustment for baseline calcium intake; age was not included in the models because its inclusion did not affect the model estimates.

Data from the substudy indicate that the participants had intermediate 25-hydroxycholecalciferol levels at baseline, typical of community-dwelling older women of the region and typical of older women in Northern Europe and North America. The intervention effectively increased background 25-hydroxycholecalciferol levels. Predictably, the levels increased substantially 1 month after dosing and thereafter declined toward baseline but remaining on average 41% higher than levels in the placebo group at 12 months. The pattern is consistent with serial measurements done in older New Zealanders supplemented with 500 000 IU cholecalciferol.

By 3 months, the after-dose median 25-hydroxycholecalciferol levels decreased to approximately 90 nmol/L in the vitamin D group.

**Adverse Events**

A similar number of participants in each group reported at least 1 adverse event: 19.7% in the vitamin D and 17.8% in the placebo group. The most common adverse events were injury including fracture—15.2% (172 of 1131) of women taking vitamin D vs 12.1% (136 of 1125) taking placebo ($P=.03$)—and cardiovascular events—1.5% (171 of 1131) vs 1.2% (13 of 1125), respectively. Seven women (0.6%) in the vitamin D group vs 10 (0.9%) in the placebo group were diagnosed with cancer.

Serious adverse events (International Conference on Harmonization/WHO Good Clinical Practice definition including hospitalization or death) did not differ significantly: 244 among women taking vitamin D vs 207 taking placebo ($P=.06$). Eighty-seven participants died during the study, 40 taking vitamin D vs 47 taking placebo. None of the serious adverse events affected the model estimates.

At the end of the intervention, participants categorized into 25-hydroxycholecalciferol status were (vitamin D group, $n=74$ vs placebo group, $n=57$, respectively) 25 nmol/L or less: 4% vs 3.5%; 26 to 50 nmol/L: 41.9% vs 57.9%; 51 to 75 nmol/L: 44.5% vs 33.3%; 75 nmol/L or higher: 9.5% vs 5.3%. To convert 25-hydroxycholecalciferol from nmol/L to ng/mL, divide by 2.496.

**Figure 4.** Serum 25-Hydroxycholecalciferol Levels Before Dose, and at 1, 3, and 12 Months After Dose

The points refer to the median level of 25-hydroxycholecalciferol at the time of blood sampling and the error bars represent the interquartile range. These 7 blood sampling time points took place in 2006, 2007, and 2008, and refer to the biochemistry substudy participants.
(HR, 1.59). No effect on falls was observed; however, falls were a secondary outcome and ascertainment was based on 6-month recall. Baseline and changes in 25-hydroxycholecalciferol and PTH levels were very similar to our results. Another common feature was that calcium supplements were not given. Whether calcium supplementation is beneficial in vitamin D intervention studies is uncertain. Studies that have shown reductions in fracture with vitamin D therapy have variously used or not used a calcium supplement. The RECORD (Randomised Evaluation of Calcium or Vitamin D) study showed no benefit of adding calcium to vitamin D, using a factorial randomized study design.

The study of Chapuy et al treated female nursing home residents (mean 25-hydroxycholecalciferol level, 36 nmol/L) with 800 IU of oral cholecalciferol plus 1.2 g of calcium or placebo taken daily. Hip and nonvertebral fractures were significantly reduced by about 25%. Likewise, in community-dwelling men and women randomized to receive 100 000 IU of oral cholecalciferol in 4 monthly doses, Trivedi et al showed reductions in any fracture and fracture at the hip, wrist, forearm, or spine. Other studies report either reductions or no effect in fracture rates in the active groups. The Women’s Health Initiative study showed no effect of daily calcium plus 400 IU of cholecalciferol on fractures. The RECORD study showed no effect in secondary prevention of fractures or falls in elderly participants treated daily with 800 IU of cholecalciferol alone, cholecalciferol plus calcium, or calcium alone, although only 54% were still taking study medication at 24 months. Other studies using intermittent oral vitamin D in older people living in residential care did not show any reduction in fractures.

Meta-analyses suggest that there is a threshold level for vitamin D supplementation of more than 400 IU daily for fracture risk reduction and that reductions in hip and nonvertebral fractures are independent of calcium supplementation. Doses of 700 to 800 IU daily reduced the risk of non-vertebral and hip fractures with stronger evidence of benefit in reducing hip fracture risk when the analysis was restricted to institutionalized adults. By contrast, a Cochrane review concluded that vitamin D therapy alone appeared unlikely to be effective in preventing fracture.

Evidence of risk reduction of falls with vitamin D supplementation with and without calcium is also inconsistent. Overall there appears to be an 11% to 19% reduction in fall risk with supplementation and a possible dose threshold of 700 to 1000 IU daily. No fall risk reduction was observed for doses of less than 700 IU or achieved serum 25-hydroxycholecalciferol levels of less than 60 nmol/L, consistent with an earlier review of trials using varying doses of vitamin D that concluded that there was insufficient evidence that cholecalciferol treatment reduced falls. Currently 600 IU (15 μg) per day is recommended for adults 70 years or older in the United States and Canada with an upper limit of 2000 IU per day (~700 000 IU per year). Cholecalciferol 1000 IU is listed on the Australian Register of therapeutic goods. Although our results cannot necessarily be applied to high-dose vitamin D administered in divided doses over the year, they suggest that further study to assess safety is needed.

The major strength of our study is that it was a large randomized, double-blind, placebo-controlled trial. Falls and fracture ascertainment were robust although nonclinical vertebral fractures would have been missed. The pragmatic design of the study provided high potential for translation into public health policy and clinical practice. The main weaknesses of the study are also related to its pragmatic design—the participants were not evaluated at the study center so that baseline clinical information may have been missed. Biochemical assessment of all participants was not possible. We do not expect that any participants reached toxic levels of 25-hydroxycholecalciferol of 375 to 500 nmol/L because the highest level at 1 month in the biochemistry substudy was 208 nmol/L. Pharmacokinetic studies in humans given a single, large oral dose of cholecalciferol indicate that 25-hydroxycholecalciferol levels peak at 7 to 21 days and thereafter decrease slowly (half-life, 60-90 days), so it is likely the peak levels were only marginally higher than the 1-month levels. Furthermore, the incremental increase in 25-hydroxycholecalciferol is likely to be lower in those already replete prior to supplementation.

This is the first study to demonstrate increased risk of falls associated with any vitamin D intervention and the second study to demonstrate an increased fracture risk associated with annual high-dose vitamin D therapy in elderly women. Our study used the largest total annual dose of vitamin D (500 000 IU) reported in any large randomized controlled trial, raising the possibility that the adverse outcome is dose-related. The opposing outcomes of 2 studies that used the same total annual dose (300 000 IU intramuscularly) suggest that the dosing regimen (ie, 4 monthly vs annually) rather than the total dose might determine the outcome. This line of reasoning is supported by the temporal risk pattern that we observed and the fact that harm has not been reported in the numerous studies that have used more frequent dosing. Thus, it is reasonable to speculate that high serum levels of vitamin D or metabolites resulting from the large annual dose, subsequent decrease in the levels, or both might be causal. Furthermore, because the levels of 25-hydroxycholecalciferol demonstrated in this study could occur with other recommended dosing regimens, the outcome of this study suggests that safety of high-dose vitamin D supplementation warrants further study.

Author Contributions: Dr Sanders had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Sanders, Kotowicz, Young, Nicholson.
HIGH-DOSE VITAMIN D AND FALLS AND FRACTURES IN WOMEN

Acquisition of data: Sanders, Stuart. Analysis and interpretation of data: Sanders, Stuart, Williamson, Simpson, Kotowicz, Nicholson. Drafting of the manuscript: Sanders, Stuart. Critical revision of the manuscript for important intellectual content: Sanders, Williamson, Simpson, Kotowicz, Nicholson. Statistical analysis: Sanders, Stuart, Williamson, Simpson. Obtained funding: Sanders, Kotowicz, Young, Nicholson. Administrative, technical, or material support: Stuart, Nicholson. Study supervision: Sanders, Nicholson.

Financial Disclosures: None reported.

Role of the Sponsor: The funding organizations were independent of the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript.

Additional Contributions: We thank Barwon Health employees Paul Murt, B Pharm, BA, FSHP (clinical trials pharmacist), Elizabeth Merriam, BSc (study coordinator 2005 to 2006), and Cathy Verecondi (administrative officer) for their help as part of their regular duties and gratefully acknowledge the 2317 women who participated in the study.

REFERENCES